Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab in Combination With Ipilimumab in Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab in Combination With Ipilimumab in Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entinostat (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal cancer; Gynaecological cancer; HER2 negative breast cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Lung cancer; Malignant fibrous histiocytoma; Ovarian cancer; Pancreatic cancer; Parotid cancer; Perivascular epithelioid cell tumours; Rectal cancer; Salivary gland cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Uterine cancer; Vulvovaginal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Sep 2024 Planned End Date changed from 30 Aug 2024 to 17 Sep 2025.
    • 14 Sep 2023 Planned End Date changed from 22 Feb 2024 to 30 Aug 2024.
    • 23 Feb 2023 Planned End Date changed from 13 Feb 2024 to 22 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top